Alembic Pharmaceuticals receives USFDA approval for Diclofenac Sodium Topical Gel 3Percentage

31 Jul 2022 , 01:33 AM

Alembic Pharmaceuticals today announced that its wholly owned subsidiary Aleor Dermaceuticals has received final approval from the US Food Drug Administration USFDA for its Abbreviated New Drug Application ANDA for Diclofenac Sodium Topical Gel 3PercentageThe approved ANDA is therapeutically equivalent to the reference listed drug product RLD Solaraze Topical Gel 3Percentage of fougera Pharmaceuticals Inc Fougera Diclofenac Sodium Topical Gel 3Percentage is indicated for the topical treatment of actinic keratoses Sun avoidance is indicated during therapy Diclofenac Sodium Topical Gel 3Percentage has an estimated market size of US$10 million for twelve months ending Mar 2022 according to IQVIA